FAQ Page

Privacy Policy

Cookie Policy

Terms and Conditions

Research Ethics & Consent

Data Protection & Security

Manifest for Government & Grants

Manifest for Investors

Manifest for Investors

Last updated: 5 September 2025

Introduction

Hesperion is a research-driven initiative based in Norway with a global outlook. We are building the data and AI infrastructure needed to transform the diagnosis and treatment of autoimmune diseases. This Manifest explains why Hesperion represents a unique opportunity for investors who want to combine financial return with measurable impact on health and society.

1. The market opportunity

  • Autoimmune diseases affect 5–10% of the global population, with rising prevalence and major unmet needs in diagnosis and therapy.
  • Current treatments are expensive, non-curative, and often ineffective for large patient subgroups.
  • Global spending on autoimmune therapeutics exceeds $100 billion annually and continues to grow.
  • The diagnostic market for precision medicine is expected to expand rapidly, driven by AI, biomarkers, and big data solutions.

2. Hesperion’s unique approach

  • Endotype-first strategy: Instead of treating “diseases” as one entity, we break them down into biological subtypes, enabling true precision medicine.
  • Data ecosystems: We combine clinical records, biomarker data, digital health signals, and patient-reported outcomes into a secure research platform.
  • AI-powered discovery: Machine learning uncovers hidden patterns that explain disease progression and treatment response.
  • Norway-first credibility: We start in a highly trusted, GDPR-strong environment, then scale globally.

3. Business and impact model

  • Licensing & partnerships: Collaborations with pharma, biotech, and healthcare providers to accelerate drug development and patient stratification.
  • Platform-as-a-service: Secure data and analytics infrastructure available for academic and industry partners.
  • Grant leverage: Government and EU grants de-risk early development, allowing private investment to scale validated concepts.
  • Impact return: Every investment contributes not only to financial growth but also to improved patient care and reduced healthcare costs.

4. Roadmap

  • 2025–2026: Establish core data platform, build initial Norwegian patient cohorts, and publish first endotype research.
  • 2026–2027: Expand European collaborations, pilot AI-based predictive models, secure first industry partnerships.
  • 2027–2030: Global scale-up, commercialization of precision diagnostic tools, integration with pharmaceutical R&D pipelines.

5. Why invest now

  • Early entry into a high-growth sector where AI + healthcare data are redefining entire markets.
  • Opportunity to back a project with Norwegian credibility and global scalability.
  • Attractive risk-sharing: public grant funding complements and amplifies private investment.
  • Alignment with ESG and impact investing mandates through direct contributions to UN Sustainable Development Goals (SDG 3: Good Health and Well-being).

6. Our commitment to investors

We operate with full transparency and measurable milestones. Investor capital is used responsibly to scale technology, partnerships, and research impact. Our governance structure ensures compliance with GDPR, Norwegian law, and international standards. Most importantly, we are committed to delivering both financial return and social value.

Contact

For investor relations, please contact:
Email: kontakt@hesperion.no
Address: Østbyveien 22b, 3280 Tjodalyng, Norway

By investing in Hesperion, you are investing in the future of precision medicine, data-driven science, and better outcomes for millions of patients worldwide.